Novel effects of gefitinib on mucin production in bronchioloalveolar carcinoma; two case reports
Novel effects of gefitinib on mucin production in bronchioloalveolar carcinoma; two case reports
复制标题
DOI：
10.1016/j.lungcan.2004.11.027
复制
发表时间：
2005-07-01
期刊：
影响因子：
5.3
通讯作者：
Kohno, S
中科院分区：
文献类型：
--
作者：
Kitazaki, T;Fukuda, M;Kohno, S
两名日本女性主诉咳嗽和支气管炎，胸部X线片显示肺部浸润。经支气管肺活检确诊为细支气管肺泡癌。经全身化疗后症状稍有改善。几个月后，他们的支气管炎和呼吸困难恶化，然后他们接受了吉非替尼治疗，吉非替尼是一种选择性表皮生长因子受体酪氨酸激酶抑制剂。支气管扩张和呼吸困难在吉非替尼治疗后24小时内得到改善，其中1例患者在6小时后改善明显，另1例患者在24小时后改善明显。此后，他们的放射学结果显示逐渐改善。支气管炎的快速缓解先于放射学结果的改善。这些观察结果表明，吉非替尼可以抑制粘蛋白的产生，以及发挥抗增殖活性对细支气管肺泡癌。(c)2005爱思唯尔爱尔兰有限公司保留所有权利。
Two Japanese females complained of cough and bronchorrhea for which chest radiographs showed infiltrate in the lungs. The patients were subsequently diagnosed as having bronchioloalveolar carcinoma by transbronchial lung biopsy. After receiving systemic chemotherapy, their symptoms were slightly improved. A few months later, their bronchorrhea and dyspnea worsened, and they were then treated with gefitinib, a selective epidermal growth factor receptor tyrosine kinase inhibitor. Bronchorrhea and dyspnea were improved within 24 h after treatment with gefitinib where the improvement was evident after 6 h for one patient and 24 h for the other patient. Thereafter, their radiological findings showed gradual improvement. Rapid relief of bronchorrhea preceded the improvement seen by the radiological findings. These observations suggest that gefitinib may inhibit mucin production as well as exert anti-proliferative activity against bronchiotoalveolar carcinoma. (c) 2005 Elsevier Ireland Ltd. All rights reserved.